BioSpace News Archive

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a fireside chat at the Raymond James 2021 Human Health Innovation Conference

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of Kishen Mehta, Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors (“Board”).

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the upcoming 2nd Annual CybeRx Series: Vaccine Forum

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present the newest trends in proteomics for biomarker discovery and translational research.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced that Mark Litton, PhD, MBA, in his capacity as Chief Operating Officer, has assumed day-to-day leadership responsibilities for the Company, effective immediately.

Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, announced that its registration statement on SEC Form S-4 (the “Registration Statement”) filed with U.S. Securities and Exchange Commission (the “SEC”) in connection with its previously announced merger with Cytocom Inc.

Rising prevalence of dental problems globally and increased awareness about oral hygiene are expected to bolster market growth.

Increasing focus on digitalizing the process of medical clinical trial outcomes coupled with advancements in eCOA applications are key factors driving market growth.

Technological advancements in molecular testing techniques and increasing prevalence of different types of cancer and neurological disorders are key factors fueling global market growth.